ArticleNature medicine2018
Tumors evading CARs-the chase is on.
Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Overcoming T cell exhaustion and senescence in CAR T cell therapy for solid tumors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- CAR T cell cancer immunotherapy: who does the job?Frontiers in immunology · 2026Review
- Use of a Foamy-Virus Vector System to Produce an 'Off-the-Shelf' Fcγ-CR-T Cell Product for the Treatment of Haematological and Solid Tumour Malignancies.Immunology · 2025Article
- Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Review
- Monoallelic deletion of BCMA is a frequent feature in multiple myeloma.Blood advances · 2023Article
- Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer.Military Medical Research · 2023Review
- CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy.International journal of molecular sciences · 2023Review
- Fine-tuning the antigen sensitivity of CAR T cells: emerging strategies and current challenges.Frontiers in immunology · 2023Review
- Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells.Cancers · 2022Article
- Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.Stem cell research & therapy · 2022Review
- Clinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions.Current opinion in hematology · 2022Review
- Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia.Cancer immunology, immunotherapy : CII · 2022Article
- CAR T Cell Immunotherapy Beyond Haematological Malignancy.Immune network · 2022Review
- Impact ofJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Article
- Immunity beyond cancer cells: perspective from tumor tissue.Trends in cancer · 2021Review
- CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities.Cellular oncology (Dordrecht, Netherlands) · 2021Review
- Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges.Frontiers in immunology · 2021Review
- A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.Frontiers in immunology · 2021Review
- Immunomodulators in Lymphoma.Current treatment options in oncology · 2020Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
30297897What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.